Italia markets closed

JNJ Jan 2025 165.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,1700+0,1700 (+8,50%)
Alla chiusura: 03:08PM EDT
Schermo intero
Chiusura precedente2,0000
Aperto2,0100
Denaro1,9300
Domanda2,5000
Prezzo d'esercizio165,00
Scadenza2025-01-17
Min-Max giorno2,0100 - 2,4400
Contratto - Min-MaxN/D
Volume81
Open Interest3,61k
  • GlobeNewswire

    Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®

    According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than February 21, 2025 REYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA